Towards the development of specific antidotes: Idarucizumab for reversal of dabigatran effects

• References

• 1 Beyer-Westendorf J, Ageno W. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Thromb Haemost 2015; 113: 231-246.
• 2 Skjoth F, Larsen TB, Rasmussen LH. et al. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2014; 111: 981-988.
• 3 Schulman S. New oral anticoagulant agents – general features and outcomes in subsets of patients. Thromb Haemost 2014; 111: 575-582.
• 4 Ferrandis R, Castillo J, de Andres J. et al. The perioperative management of new direct oral anticoagulants: a question without answers. Thromb Haemost 2013; 110: 515-522.
• 5 Honickel M, Treutler S, van Ryn J. et al. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab. Thromb Haemost 2015; 113: 728-740.
• 6 Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?. Thromb Haemost 2014; 111: 189-198.
• 7 Perzborn E, Gruber A, Tinel H. et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 2013; 110: 162-172.
• 8 Majeed A, Meijer K, Larrazabal R. et al. Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. Thromb Haemost 2014; 111: 233-239.
• 9 Marlu R, Hodaj E, Paris A. et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-224.
• 10 Miesbach W, Seifried E. New direct oral anticoagulants--current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost 2012; 108: 625-632.
• 11 Zhou W, Schwarting S, Illanes S. et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599.
• 12 Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011; 123: 1436-1450.
• 13 Khadzhynov D, Wagner F, Formella S. et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with endstage renal disease. Thromb Haemost 2013; 109: 596-605.
• 14 Glund S, Moschetti V, Norris S. et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015; 113: 943-951.
• 15 Lu G, DeGuzman FR, Hollenbach SJ. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nature Med 2013; 19: 446-451.